| CS | calf serum; campomelic syndrome; carcinoid syndrome; cardiogenic shock; caries-susceptible; carotid ... |
|---|---|
| PDMS | patient data management system; pharmacokinetic drug monitoring service; polydimethylsiloxane |
| DC | daily census; data communication; data conversion; decrease; deep compartment; Dental Corps; deoxych... |
| DDP | cisplatin; density-dependent phosphoprotein; difficult denture patient; digital data processing; dis... |
| HDS | Hamilton Depression Scale; Health Data Services; health delivery system; Healthcare Data Systems; he... |
| monitoring, intraoperative | The constant checking on the state or condition of a patient during the course of a surgical operation (e.g., checking of vital signs). (12 Dec 1998) |
|---|---|
| monitoring, physiologic | The continuous measurement of physiological processes, blood pressure, heart rate, renal output, reflexes, respiration, etc., in a patient or experimental animal; includes pharmacologic monitoring, the measurement of administered drugs or their metabolites in the blood, tissues, or urine. (12 Dec 1998) |
| Holter monitoring | <cardiology, investigation> A test which measures the heart rhythm (ECG) over a 24 hour period of time while the patient records their symptoms and activities in a diary. A small portable ECG device is worn in a pouch around the neck. After the test is complete, a correlation is made between the symptoms (or activities) recorded and the ECG pattern that was obtained simultaneously. (27 Sep 1997) |
| drug monitoring | The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically. (12 Dec 1998) |
| intraocular pressure monitoring | <ophthalmology, technique> This is procedure which measures the pressure inside the eyes. This is a screening test for glaucoma. This test is performed by an ophthalmologist. (27 Sep 1997) |
| environmental monitoring | The monitoring of the level of toxicants, pollutants, or other harmful chemicals in the environment or workplace by measuring the amounts of these toxicants in the bodies of people and animals in that environment, among other methods. It also includes the measurement of environmental exposure. Humans and animals are used as indicators of toxic levels of undesirable chemicals. (12 Dec 1998) |
| uterine monitoring | Measurement or recording of contraction activity of the uterine muscle. It is used to determine progress of labour and assess status of pregnancy. It is also used in conjunction with foetal monitoring to determine foetal response to stress of maternal uterine contractions. (12 Dec 1998) |
| foetal monitoring | Physiologic or biochemical monitoring of the foetus. It is usually done during labour and may be performed in conjunction with the monitoring of uterine activity. It may also be performed prenatally as when the mother is undergoing surgery. (12 Dec 1998) |
| Addison's clinical planes | A series of plane's used as landmarks in thoracoabdominal topography; the trunk is divided vertically by a median plane from the upper border of the manubrium of the sternum to the pubic symphysis, by a lateral plane drawn vertically on either side through a point half way between the anterior superior iliac spine and the median plane at the interspinal plane, and by an interspinal plane passing vertically through the anterior superior iliac spine on either side; transversely the trunk is divided by a transthoracic plane passing across the thorax 3.2 cm above the lower border of the body of the sternum, by a transpyloric plane midway between the jugular notch of the sternum and the pubic symphysis, corresponding to the disc between the first and second lumbar vertebrae, and by an intertubercular plane passing through the iliac tubercles and cutting usually the fifth lumbar vertebra; the plane's formed on these lines, and also on transverse plane's cutting the upper edge of the manubrium and the upper edge of the pubic symphysis, constitute the clinical plane's of Addison. (05 Mar 2000) |
| pathology, clinical | A subspecialty of pathology which deals with the laboratory analysis of specimens of human blood and other fluids. (12 Dec 1998) |
| chemistry, clinical | The specialty of analytical chemistry applied to assays of physiologically important substances found in blood, urine, tissues, and other biological fluids for the purpose of aiding the physician in making a diagnosis or following therapy. (12 Dec 1998) |
| pharmacology, clinical | The branch of pharmacology that deals directly with the effectiveness and safety of drugs in humans. (12 Dec 1998) |
| phase I clinical trial | <pharmacology> The earliest stage clinical trial for studying an experimental drug in humans. Phase I trials are generally comparatively small and are used to determine toxicity and maximum dose. They provide an initial evaluation of a drug's safety and pharmacokinetics-how the drug is absorbed, what tissues it reaches and how long it takes to leave the body. Such studies also usually test various doses of the drug (dose-ranging) to obtain an indication of the appropriate dose to use in later studies. The patients in these trials usually have advanced disease and have already received best available chemotherapy, therefore, seeing a repose is significant partially because this means there is a lack of cross-resistance between two anti-cancer drugs. (31 Dec 1997) |
| phase II clinical trial | <pharmacology> Usually focus on the activity of the new product as a single agent in a noncomparative, open study. (31 Dec 1997) |
| phase III clinical trial | <pharmacology> An advanced stage clinical trial that should conclusively show how well a drug works as compared to other treatments. Phase III trials are large, frequently multi-institution tests. They generally compare the relative value of the new drug compared with the current standard treatment and measure whether a new drug extends survival or otherwise improves the health of patients on treatment (clinical improvement) rather than just provide surrogate marker data. These studies generally last longer and are larger than phase II trials. (31 Dec 1997) |